Potent and reversible NIMA related kinase 2 (Nek2) inhibitor (IC50 = 56 nM). Induces increased mitotic abnormalities and mitotic delay. Cell permeable and active in vivo.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 292.3. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.42 mL||17.11 mL||34.21 mL|
|5 mM||0.68 mL||3.42 mL||6.84 mL|
|10 mM||0.34 mL||1.71 mL||3.42 mL|
|50 mM||0.07 mL||0.34 mL||0.68 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Lebraud et al (2014) Model system for irreversible inhibition of Nek2: thiol addition to ethynylpurines and related substituted heterocycles. Org.Biomol.Chem. 12 141 PMID: 24213855
If you know of a relevant reference for NCL 00017509, please let us know.
View Related Products by Product Action
Keywords: NCL 00017509, supplier, NCL00017509, NIMA, related, kinase, 2, NEK2, inhibitors, inhibits, mitotic, delay, Nek2, Kinase, Nek2, Kinase, Tocris Bioscience
Citations for NCL 00017509
Citations are publications that use Tocris products.
Currently there are no citations for NCL 00017509. Do you know of a great paper that uses NCL 00017509 from Tocris? If so please let us know.
Literature in this Area
Cancer Metabolism Poster
Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the main targets for cancer metabolism researchers. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways. These distinct metabolic circuits could provide viable cancer therapeutic targets.
Cell Cycle & DNA Damage Repair Poster
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
Epigenetics in Cancer Poster
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.